CompletedPHASE1, PHASE2NCT02061137
Study to Assess Safety and Efficacy of Fingolimod in Children With Rett Syndrome
Studying Rett syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University Hospital, Basel, Switzerland
- Principal Investigator
- Ludwig Kappos, Prof.Department of Neurology - University Hospital Basel - Switzerland
- Intervention
- fingolimod (FTY720)(drug)
- Enrollment
- 6 enrolled
- Eligibility
- 6 years · All sexes
- Timeline
- 2013 – 2018
Study locations (1)
- Department of Neuropediatrics - University Children's Hospital, Basel, Switzerland
Collaborators
Novartis
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02061137 on ClinicalTrials.govOther trials for Rett syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT06840496To Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett SyndromeBiomed Industries, Inc.
- RECRUITINGPHASE2NCT07430046Repurposing Mirtazapine in Rett SyndromeUniversity of Trieste
- RECRUITINGNCT06338267Validating Innovative Biosensors for Rett Autonomic Symptom TrackingRett Syndrome Research Trust
- RECRUITINGEARLY PHASE1NCT06856759Single-Dose AAV-MECP2 Safety/Tolerability and Efficacy in Rett SyndromeGuangzhou Women and Children's Medical Center
- RECRUITINGNCT06705816Cognitive Function in Rett Syndrome During Trofinetide TreatmentUniversity of Minnesota
- ENROLLING BY INVITATIONNANCT06739434GCB-002 in Treatment of Patients With Rett SyndromeGenecombio Ltd.
- ACTIVE NOT RECRUITINGNANCT07418905Technology-supported Motor Rehabilitation for People With Rett SyndromeGeorgetown University
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06152237Safety and Efficacy of TSHA-102 in Pediatric Females With Rett Syndrome (REVEAL Pediatric Study)Taysha Gene Therapies, Inc.